Charles Schwab Investment Management Inc. Grows Position in AstraZeneca PLC (NASDAQ:AZN)

Charles Schwab Investment Management Inc. boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 0.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,784,235 shares of the company’s stock after buying an additional 8,830 shares during the period. Charles Schwab Investment Management Inc.’s holdings in AstraZeneca were worth $139,010,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Martin Investment Management LLC raised its stake in shares of AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after acquiring an additional 7,615 shares during the period. Integrated Advisors Network LLC lifted its stake in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Creative Planning boosted its position in shares of AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after buying an additional 16,692 shares during the period. Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at $269,000. Finally, Cetera Advisors LLC grew its stake in shares of AstraZeneca by 124.5% in the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock valued at $6,657,000 after buying an additional 54,488 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AZN. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. TD Cowen raised their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 2.1 %

Shares of NASDAQ:AZN opened at $65.63 on Monday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock has a market cap of $203.49 billion, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. The firm’s 50 day moving average price is $73.44 and its 200 day moving average price is $77.80.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.87 EPS. As a group, equities research analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.